1.
Clin Lymphoma Myeloma Leuk
; 22(2): 129-132, 2022 02.
Article
in English
| MEDLINE
| ID: mdl-34670732
2.
Eur J Haematol
; 107(3): 370-373, 2021 Sep.
Article
in English
| MEDLINE
| ID: mdl-34018260
Subject(s)
Adenine/analogs & derivatives , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Central Nervous System Neoplasms/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Neoplasm Recurrence, Local/drug therapy , Neoplasms, Second Primary/drug therapy , Piperidines/therapeutic use , Temozolomide/therapeutic use , Adenine/therapeutic use , Adult , Aged , Aged, 80 and over , Central Nervous System Neoplasms/mortality , Central Nervous System Neoplasms/pathology , Female , Humans , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/pathology , Prognosis , Retrospective Studies , Survival Analysis
3.
Presse Med
; 48(7-8 Pt 1): 825-831, 2019.
Article
in French
| MEDLINE
| ID: mdl-31447337
ABSTRACT
Diagnosis criteria have been revised in 2014 and allow the treatment of some asymptomatic patients. Since 2015, a new prognostic score includes tumor plasma cells chromosomal abnormalities. It helps in the distinction between "standard risk" and "high risk" myelomas. Scanner, MRI and Pet Scan are the radiological reference exams to evaluate bone involvement. Alkylating agents, immunomodulators, proteasome inhibitors, and monoclonal antibodies became the most important antitumoral treatments. Risk notion will become more and more important for therapeutic choices. These choices will depend on residual disease evaluation. The next decade will be the immunotherapies development decade.